The use of phosphodiesterase type 5 inhibitors for erectile dysfunction

Current Opinion in Urology

Volumn 14, Issue 6, 2004, Pages 357-359

  Montorsi, Francesco ^a   Briganti, Alberto ^a   Salonia, Andrea ^a   Montorsi, Piero ^b   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

COUNSELING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EDITORIAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; SMOOTH MUSCLE RELAXATION; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 8644249185     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200411000-00011     Document Type: Editorial

References (10)

1. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328:1037.
2. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14 (Suppl 1):S43-S52.
3. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44:360-364.
4. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur Urol 2003; 44:352-354.
5. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003; 92:19M-25M.
6. Mirone V, Van Halen H, Moncada I, et al. For the SURE Study Investigators. Efficacy and safety of two dosing regimens with tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries [abstract]. Eur Urol 2004; 2 (Suppl 3):104.
7. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93:1276-1281.
8. Montorsi F, Padma-Nathan H, Buvat J, et al. For the Vardenafil Study Group. Earliest time to onset of action leading to successful intercourse with Vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med (in press).
9. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19:32-39.
10. Mulhall JP. Deciphering erectile dysfunction drug trials. J Urol 2003; 170:353-358.